lobbying_activities: 1878931

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1878931	faa59872-596c-425f-8baf-54b91ce75d15	Q3	MEHLMAN CONSULTING, INC.	284950	THE CAMPAIGN FOR SUSTAINABLE RX PRICING	2016	third_quarter	PHA	Issues related to transparency and competition in the prescription drug market. S.3056, Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES). S. 3335, Fair Accountability and Innovative Research Drug Pricing Act of 2016 (FAIR). Food and Drug Administration Appropriations Act.	HOUSE OF REPRESENTATIVES,SENATE	80000		0	0	2016-10-17T11:32:41.330000-04:00